Aranesp is the trade name for Darbepoetin alfa, a synthetic version of erythropoietin, which stimulates the production of red blood cells. Aranesp has been used since its approval by the U.S. Food and Drug Administration (FDA) in 2001 to treat patients with anemia, as well as chronic renal failure. It has been frequently prescribed to individuals suffering anemia as a byproduct of chemotherapy.
The FDA has required black box warnings on all sales of Darbepoetin alfa in the United States, citing a number of potential adverse health risks, including:
- Myocardial infarction, or heart attack, as well as congestive heart failure
Hypertension (high blood pressure), with increased risk of stroke
- Venous thromboembolism
- Thrombosis of vascular access
- Tumor progression or recurrence
If you experienced side effects after being prescribed Aranesp, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.
Defective Drugs & Medical Devices Topics
The 25th Amendment to the United States Constitution Is in the News
The Constitutional Process for Replacing a President Who Lacks Capacity to Serve The United States C…Read More 15 Oct 2020, Thursday
The Legal Consequences of Voting Twice
Why You Shouldn’t Follow Trump’s Suggestion to “Test Integrity of Electoral System” | P…Read More 21 Sep 2020, Monday
Medical Malpractice: How It Differs from Other Negligence Claims
The Standard of Care – What You Must Prove to Recover for Your Losses When you’re hurt in an…Read More 21 Aug 2020, Friday